Asset profile
Balstilimab
Monoclonal antibody
Earlyevidence
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Cervical Cancer · Phase 2
Featured evidence outside covered markets:BATTMAN (NCT07152821) · Colorectal Cancer · Phase 3 · ungradedCIME (NCT06346197) · Gastric Cancer · Phase 3 · ungraded
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
85 competitors in this universe: 22 direct rivals (same mechanism and indication), 1 same-class, 62 same-indication; 62 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Balstilimab: this drug | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Nivolumab | Approved | Monoclonal antibody | PD-1 | ||
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | ||
| Pembrolizumab Berahyaluronidase Alfa | Approved | Monoclonal antibody | PD-1 | ||
| Retifanlimab | Approved | Monoclonal antibody | PD-1 | ||
| Toripalimab | Approved | Monoclonal antibody | PD-1 | ||
| Abp 234 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| CT-P51 | Phase 3 | Small molecule | PD-1 | ||
| Dostarlimab | Phase 3 | Monoclonal antibody | PD-1 | ||
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | ||
| MB12 | Phase 3 | Monoclonal antibody | PD-1 | ||
| Penpulimab | Phase 3 | Monoclonal antibody | PD-1 |
…and 70 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Cemiplimab · Non-Small Cell Lung Cancervs Nivolumab · Non-Small Cell Lung Cancervs Pembrolizumab · Non-Small Cell Lung Cancervs Retifanlimab · Non-Small Cell Lung Cancervs Toripalimab · Non-Small Cell Lung Cancervs Camrelizumab · Non-Small Cell Lung Cancer
6 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(30 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
December 2026 (2)
Phase 1/2Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer …Active not recruiting
Est. primary completion 2026-12 · NCT05205330 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer Metastatic, Liver Metastases, Colorectal CancerRecruiting
Est. primary completion 2026-12 · NCT06300463 · CT.gov ↗
What to watch
2027 (12)
January 2027 (3)
Phase 1Non-MSI-H or pMMR Colorectal Cancer With Liver MetastasisRecruiting
Est. primary completion 2027-01-01 · NCT07128355 · CT.gov ↗
What to watch
Phase 2Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal CarcinomaRecruiting
Est. primary completion 2027-01-01 · NCT07735624 · CT.gov ↗
What to watch
Phase 1Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8Recruiting
Est. primary completion 2027-01-15 · NCT06336902 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue SarcomaActive not recruiting
Est. primary completion 2027-04-07 · NCT04028063 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Colorectal Cancer, Resectable Colorectal CarcinomaRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
Phase 2Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Stage IIB Colon Cancer AJCC v8 …Recruiting
Est. primary completion 2027-05-27 · NCT07595874 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma …Active not recruiting
Est. primary completion 2027-06-16 · NCT05627635 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)Recruiting
Est. primary completion 2027-07-31 · NCT06589440 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer …Active not recruiting
Est. primary completion 2027-08-01 · NCT06251973 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-09 · NCT05608044 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic CancerRecruiting
Est. primary completion 2027-10 · NCT06782555 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8Recruiting
Est. primary completion 2027-11-05 · NCT06780787 · CT.gov ↗
What to watch
2028 (8)
February 2028 (2)
April 2028 (1)
Phase 1Colorectal Cancer MetastaticRecruiting
Est. primary completion 2028-04-15 · NCT07193862 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Gastric Cancer, MSI-H, Metastatic Cancer, Advanced CancerRecruiting
Est. primary completion 2028-05-15 · NCT06346197 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2028-07 · NCT06268015 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Colorectal Cancer MetastaticRecruiting
Est. primary completion 2028-09 · NCT07550088 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2028-12 · NCT06782932 · CT.gov ↗
What to watch
Phase 2Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8Recruiting
Est. primary completion 2028-12-31 · NCT07516366 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 2/3Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid TumorsRecruiting
Est. primary completion 2029-01-29 · NCT06279130 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8Recruiting
Est. primary completion 2029-08-28 · NCT07551596 · CT.gov ↗
What to watch
September 2029 (1)
November 2029 (1)
Phase 1Colorectal Cancer, Pancreatic CancerRecruiting
Est. primary completion 2029-11-01 · NCT06411691 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-04 · NCT06322108 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic CancerRecruiting
Est. primary completion 2030-08-01 · NCT06843551 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Colorectal Cancer, Rectal CancerRecruiting
Est. primary completion 2030-11 · NCT07227636 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 2Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma MultiformeActive not recruiting
Est. primary completion 2031-07-31 · NCT05864534 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.